DBV Technologies

US · DBVT #3611 by market cap Listed 2015

9.77 -0.21 -2.10%

Live - 5344 symbols - heartbeat 20s ago · 2026-10-08 08:01

Pre-market 9.73 -0.41%

After-hours 9.32 -4.61%

Overnight 9.62 -1.54%

Market cap: 614.03M
P/E (TTM): -2.79
P/B: 3.83
EPS: -5.25
Div yield: 0.00%
52W pos: 1%

Reader sentiment Are you bullish or bearish on DBVT?

Anonymous reader poll. Unscientific, not investment advice.

About DBV Technologies

DBV Technologies SA is a clinical-stage biopharmaceutical company, which engages in the research and development of epicutaneous immunotherapy products. The firm focuses on the development of Viaskin, an electrostatic patch, which may offer a convenient, self-administered, and non-invasive immunotherapy to patients. It also designs a robust clinical development program that includes ongoing clinical trials of Viaskin peanut, and Viaskin milk, as well as pre-clinical development of Viaskin egg. The company was founded by Pierre-Henri Benhamou, Stéphane Benhamou, Bertrand Dupont, Christophe Dupont, and Pierre-Yves Vannerom on March 29, 2002 and is headquartered in Chatillon, France.

Founded: 2002
CEO: Mr. Daniel Tasse
Employees: 126
Headquarters: Chatillon, HF, France
Fiscal year end: 12-31
Website: dbv-technologies.com

Company profile

Exchange: US
Symbol: DBVT
Market-cap rank: #3611
Listing date: 2015-04-02
Market cap: 614.03M
Float cap: 377.17M
Shares out: 62.85M
Float shares: 38.61M

Sectors & themes

Biotechnology Stocks tradable only on moomoo Fractional Shares JP

Browse all sectors & themes

Quote time 2026-10-08 08:01:50 · For reference only, not investment advice and not tailored to your situation.